Argent BioPharma Limited Stock Australian S.E.

Equities

MXC

AU000000MXC6

Pharmaceuticals

Market Closed - Australian S.E. 08:30:47 2024-04-16 pm EDT 5-day change 1st Jan Change
0.43 AUD -1.15% Intraday chart for Argent BioPharma Limited 0.00% -9.47%
Sales 2022 4.73M 3.04M Sales 2023 3.39M 2.18M Capitalization 16.75M 10.78M
Net income 2022 -20M -12.87M Net income 2023 -20M -12.87M EV / Sales 2022 9.75 x
Net Debt 2022 2.47M 1.59M Net Debt 2023 9.51M 6.12M EV / Sales 2023 7.75 x
P/E ratio 2022
-2.02 x
P/E ratio 2023
-0.7 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 9.44%
More Fundamentals * Assessed data
Dynamic Chart
1 week+3.61%
Current month+4.88%
1 month-1.15%
6 months-71.33%
Current year-9.47%
More quotes
1 week
0.41
Extreme 0.41
0.45
1 month
0.39
Extreme 0.39
0.45
3 years
0.30
Extreme 0.3
67.00
5 years
0.30
Extreme 0.3
130.00
10 years
0.30
Extreme 0.3
130.00
More quotes
Date Price Change Volume
24-04-16 0.43 -1.15% 2
24-04-16 0.435 -2.25% 18,828
24-04-15 0.445 0.00% 11,403
24-04-12 0.445 +2.30% 49,208
24-04-11 0.435 +4.82% 8,542

Delayed Quote Australian S.E., April 16, 2024 at 08:30 pm EDT

More quotes
Argent BioPharma Ltd, formerly MGC Pharmaceuticals Ltd, is an Australia-based drug discovery company. The Company is focused on developing and supplying accessible and ethically produced plant-derived medicines, combining in-house research with technologies. Its approach combines in-house research with technology, all discovering and producing treatments for unmet medical conditions. Its investigational medicinal (IMPs) products include CannEpil, CimetrA and CogniCann. CimetrA is a phyto medicine based on natural ingredients from Curcumin and Boswellia serrata, delivered in the nanoparticle delivery system, which is being developed for acute lung injury and acute respiratory distress syndrome (ARDS). CannEpil is a phyto medicine based on phytocannabinoid is being developed for the treatment of refractory epilepsy and cerebral palsy. CogniCann is a phyto medicine based on phytocannabinoids is in investigation stage as a treatment for the symptoms associated with dementia and Alzheimer.
More about the company

Annual profits - Rate of surprise